Viewing Study NCT02750358

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:12 AM
Ignite Modification Date: 2026-02-19 @ 3:17 AM
Study NCT ID: NCT02750358
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-22
First Post: 2016-04-21
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Early Stage View
None Triple Negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Enzalutamide View
None 15-307 View